Journal
CANCER CELL
Volume 22, Issue 1, Pages 7-8Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2012.06.009
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01 AI046643] Funding Source: Medline
Ask authors/readers for more resources
Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
